Notice of Proposed Sale · 144

Stoke Therapeutics, Inc.

STOKNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Oct 21, 2026Accepted Oct 21, 2026, 4:42 PM EDTFiling CIK 1623526Accession 0001950047-26-010349

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: STOKE THERAPEUTICS, INC.
Issuer CIK: 0001623526
SEC file number: 001-38938
Phone: 781-430-8200
Person for whose account securities are to be sold: EDWARD KAYE
Relationships to issuer: Former Affiliate
Street: 45 Wiggins Ave
City: Bedford
State / country code: MA
Postal code: 01730

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	1,496,042	38,418,358.56	64,526,242	10/21/2026	NASDAQ	Morgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name: Morgan Stanley Smith Barney LLC Executive Financial Services
Street: 1 New York Plaza
Street (continued): 8th Floor
City: New York
State / country code: NY
Postal code: 10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 15 reported rows
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	27,441	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	15,360	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	51,498	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	416,884	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	88,817	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	9,876	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	187,124	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	303,083	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	4,917	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	67,789	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	3	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	186,375	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	92,321	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	7,054	N	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer	37,500	N	10/21/2026	Cash

Sales reported in the preceding three months

Sales reported in the preceding three months · 1 reported row
Seller	Security	Sale date	Amount sold	Gross proceeds
Edward Kaye	Common	08/14/2026	12,567	402,521.01

Seller — prior-sale row 1, entry 1

Name: Edward Kaye
Street: 45 Wiggins Ave
City: Bedford
State / country code: MA
Postal code: 01730

Prior-sale reporting

Nothing to report for the preceding three months: N

Remarks

This Form 144 is being filed for the cashless exercise of options and subsequent sales of the underlying commencing on 10/21/2026

Notice signature

Notice date: 10/21/2026
Signed: /s/ Edward Michael Kaye

Company context

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.

Current securities

STOKNASDAQ · EQUITY · Current

Get the free weekly BCS email.